AVE

0.00%

0.3¢ avecho biotechnology limited

Investor Hub Answers, page-44

First 44 Last

Share
Profile

Follow
pakkham

12,103 Posts.

622

12/09/23

20:14

Post #: 69832146
Share

Originally posted by FrankieAlfie: ↑

Hi Paul,
there has been an announcement by BOD that their phase 2B trial for insomnia has had some successful results. They are moving towards a schedule 3 with the TGA. How does this place us? It would seem to be great validation but are we closer to being TGA approved given we are soon to start Phase 3 trials?
thank you
Avecho Biotechnology Limited
ASX:AVE
08:52AM 08/09/2023

Hi Phil,

We read the BOD results with great interest and I did have a number of interested shareholders reach out to ask what we could learn heading into our own study. Although their study failed their primary endpoints, it was validating to see a signal for improved sleep using CBD when compared to placebo, even if only in a post-hoc statistical analysis.

The two items that leapt out to us were the following; dose and powering.

BOD tested 50mg and 100mg versus placebo. Their analysis suggested that 50mg didn't work, whereas there was a signal that 100mg did, ie. you need higher doses of CBD to get improved sleep. We are using 75mg and 150mg on our trial, so we're already using a higher dose. Plus, we have our increased absorption to further increase the amount of drug absorbed. So, we're feeling pretty good that BOD's results show that we've got the dose/product correct.

On the powering side, BOD failed to get statistical significance for their primary endpoint (@ p<0.025). But, using a post-hoc analysis, they saw a subset of patients with statistically signifance changes (p<0.05). The way you increase your chances of statistical significance (assuming no change in effectiveness) is simply by dosing more patients. BOD dosed 208 patients. We are planning on dosing about 540. The increase in statistical power in our study is very large, maximising our chance of success in the primary endpoints (required for TGA approval).

In summary, BODs results appear to show that CBD works for sleep, de-risking our trial (thank you BOD!). They showed that the study ideally needs higher doses of CBD and more patients on study, which is exactly what we had planned.

Cheers,

Paul

Expand

my thoughts about >>
someone push the shares to 0.009>> insiders sold dump mode>> knowing placement was at 0.006??
then sophis dump into o,oo5,, coz they have large amount options to ex 0.012
calculated shot
..cow boys of the west by standart

AVE Price at posting: 0.5¢ Sentiment: Buy Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

LRV

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

RCE

Recce's R327 found effective against E.coli during clinical trial

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

AVA

Ava Risk Group expands US presence with A$0.7M Substation Deal

SVL

Silver Mines models five new calderas close to 396Moz Bowdens deposit

CMX

ChemX Materials kicks off first stage works at WA high purity alumina pilot

SS1

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Microcap Wrap: 5 explorers with news out today

LU7

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

There are more pages in this discussion • 5 more messages in this thread...

First 44 Last

Add AVE (ASX) to my watchlist

(20min delay)
Last 0.3¢		Change 0.000(0.00%)		Mkt cap ! $9.508M

Open	High	Low	Value	Volume
0.2¢	0.3¢	0.2¢	$3.607K	1.445M

Buyers (Bids)

No.	Vol.	Price($)
59	102396408	0.2¢

Sellers (Offers)

Price($)	Vol.	No.
0.3¢	21041400	12

View Market Depth

No.	Vol.	Price($)
59	102396408	0.002
17	66672509	0.001
0	0	0.000
0	0	0.000
0	0	0.000

Price($)	Vol.	No.
0.003	21041400	12
0.004	24596507	21
0.005	38966071	19
0.006	19592339	11
0.007	9365221	8

Last trade - 16.10pm 28/06/2024 (20 minute delay)

AVE (ASX) Chart

Investor Hub Answers, page-44

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

Recce's R327 found effective against E.coli during clinical trial

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

Ava Risk Group expands US presence with A$0.7M Substation Deal

Silver Mines models five new calderas close to 396Moz Bowdens deposit

ChemX Materials kicks off first stage works at WA high purity alumina pilot

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Microcap Wrap: 5 explorers with news out today

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Investor Hub Answers, page-44

Top Stories

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

Recce's R327 found effective against E.coli during clinical trial

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

Ava Risk Group expands US presence with A$0.7M Substation Deal

Silver Mines models five new calderas close to 396Moz Bowdens deposit

ChemX Materials kicks off first stage works at WA high purity alumina pilot

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Microcap Wrap: 5 explorers with news out today

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News